Benzinga's Top Ratings Upgrades, Downgrades For July 3, 2023
Portfolio Pulse from Benzinga Insights
Several companies have received analyst rating upgrades, downgrades, and initiations. Lazard Ltd (LAZ) and ACM Research Inc (ACMR) were upgraded by Wolfe Research and Jefferies respectively. B of A Securities, HC Wainwright & Co., and DBS Bank initiated coverage on Reneo Pharmaceuticals Inc (RPHM), LifeMD Inc (LFMD), Ensysce Biosciences Inc (ENSC), and Amazon.com Inc (AMZN) respectively, all with Buy ratings.
July 03, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACM Research Inc was upgraded from Underperform to Buy by Jefferies. The stock closed at $13.08 in the last trading period.
The upgrade in rating by Jefferies could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
DBS Bank initiated coverage on Amazon.com Inc with a Buy rating. The stock closed at $130.36 in the last trading period.
The initiation of coverage with a Buy rating by DBS Bank could lead to increased investor interest and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
HC Wainwright & Co. initiated coverage on Ensysce Biosciences Inc with a Buy rating. The stock closed at $1.80 in the last trading period.
The initiation of coverage with a Buy rating by HC Wainwright & Co. could lead to increased investor interest and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Lazard Ltd was upgraded from Underperform to Peer Perform by Wolfe Research. The stock closed at $32.00 in the last trading period.
The upgrade in rating by Wolfe Research could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
HC Wainwright & Co. initiated coverage on LifeMD Inc with a Buy rating. The stock closed at $4.35 in the last trading period.
The initiation of coverage with a Buy rating by HC Wainwright & Co. could lead to increased investor interest and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
B of A Securities initiated coverage on Reneo Pharmaceuticals Inc with a Buy rating. The stock closed at $6.56 in the last trading period.
The initiation of coverage with a Buy rating by B of A Securities could lead to increased investor interest and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100